


(I);

or a pharmaceutically acceptable salt thereof; and (b) radiation therapy; in amounts effective for treating the brain tumor.


[0012a] In one aspect, there is provided a use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a glioma in a patient in need thereof, wherein the glioma is characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in accumulation of R(-)-2-hydroxyglutarate



(I);

wherein a therapeutically effective amount of the compound is to be administered with radiation therapy; wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, and radiation therapy are to be administered concurrently or sequentially.


[0013] In another aspect, the invention provides a method for treating a brain tumor in a patient in need thereof comprising administering to the patient (a) a compound of formula (I)



(I);

or a pharmaceutically acceptable salt thereof; and (b) one or more additional therapeutic agents; in amounts effective for treating the brain tumor.


~~**[0013a]** In yet another aspect, there is provided a use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a glioma in a patient in need thereof; wherein the glioma is characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in accumulation of R(-)-2-hydroxyglutarate~~



(I);

~~wherein a therapeutically effective amount of the compound is to be administered with one or more additional therapeutic agents; wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents are to be administered concurrently or sequentially.~~


[0014] In another aspect, the invention provides a method for treating a brain tumor in a patient in need thereof comprising administering to the patient (a) a compound of formula (I)



(I);

CLAIMS

1. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating a glioma in a patient in need thereof, wherein the glioma is characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in accumulation of R(-)-2-hydroxyglutarate



(I);

wherein a therapeutically effective amount of the compound is to be administered with radiation therapy; wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, and radiation therapy are to be administered concurrently or sequentially.

2. The use of claim 1, wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, is to be administered once per day in an amount of about 500 mg.


3. The use of claim 1, wherein said radiation therapy is to be administered in the form of x-ray radiation.

4. The use of claim 1, wherein said radiation therapy is to be administered in a cumulative dose of from 30 to 60 Gy.

5. The use of claim 1, wherein the IDH1 mutation is an R132X mutation.

6. The use of claim 5, wherein the IDH1 mutation is an R132H or R132C mutation.

7. Use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating a glioma in a patient in need thereof; wherein the glioma is characterized by the presence of an IDH1 mutation, wherein the IDH1 mutation results in accumulation of R(-)-2-hydroxyglutarate,



(I);

wherein a therapeutically effective amount of the compound is to be administered with one or more additional therapeutic agents; wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, and one or more additional therapeutic agents are to be administered concurrently or sequentially.

8. The use of claim 7, wherein the one or more additional therapeutic agents is a DNA-reactive agent.

9. The use of claim 8, wherein the DNA-reactive agent is temozolomide.

10. The use of claim 9, wherein said temozolomide is to be administered in a daily dose of from 150-200 mg/m^2, based on the patient's body surface area.

11. The use of claim 7, wherein the one or more additional therapeutic agents is a PARP inhibitor.

12. The use of claim 7, wherein the one or more additional therapeutic agents is an anti-emesis agent.

13. The use of claim 7, wherein the one or more additional therapeutic agents is an anti-convulsant or anti-epileptic agent.

~~14. The use of claim 7, wherein the one or more additional therapeutic agents is a checkpoint inhibitor.~~

~~15. The use of claim 7, wherein the one or more additional therapeutic agents is PCV chemotherapy.~~

~~16. The use of claim 7, wherein the one or more additional therapeutic agents is bevacizumab.~~

~~17. The use of claim 7, wherein the one or more additional therapeutic agents is gemcitabine.~~

~~18. The use of any one of claims 7-17, wherein said compound of formula (I), or a pharmaceutically acceptable salt thereof, is to be administered once per day in an amount of about 500 mg.~~

~~19.~~7. The use of any one of claims 1 to ~~18~~6, wherein said compound of formula (I) is to be administered in non-salt form.

~~20. The use of claim 7, wherein the IDH1 mutation is an R132X mutation.~~

~~21. The use of claim 20, wherein the IDH1 mutation is an R132H or R132C mutation.~~

~~22. The use of claim 7, wherein radiation therapy is also to be administered.~~

~~23. The use of claim 22, wherein said radiation therapy is to be administered in the form of x-ray radiation.~~

~~24. The use of claim 22 or 23, wherein said radiation therapy is to be administered in a cumulative dose of from 30 to 60 Gy.~~